Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$9.9 million.

  • Ultragenyx Pharmaceutical's Other Working Capital Changes rose 2211.83% to -$9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 17082.65%. This contributed to the annual value of -$11.7 million for FY2024, which is 2345.19% up from last year.
  • Ultragenyx Pharmaceutical's Other Working Capital Changes amounted to -$9.9 million in Q3 2025, which was up 2211.83% from -$313000.0 recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Other Working Capital Changes registered a high of $22.5 million during Q4 2021, and its lowest value of -$12.7 million during Q3 2024.
  • Its 5-year average for Other Working Capital Changes is $311263.2, with a median of -$1.7 million in 2021.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Other Working Capital Changes soared by 106245.47% in 2022, and later crashed by 136262.04% in 2024.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Other Working Capital Changes (Quarter) stood at $22.5 million in 2021, then tumbled by 114.38% to -$3.2 million in 2022, then soared by 138.86% to $1.3 million in 2023, then tumbled by 57.27% to $538000.0 in 2024, then tumbled by 1941.08% to -$9.9 million in 2025.
  • Its Other Working Capital Changes stands at -$9.9 million for Q3 2025, versus -$313000.0 for Q2 2025 and $17.5 million for Q1 2025.